The American CNN network revealed that some of the Corona patients have requested to join clinical trials of COVID-19 virus drugs based on antibodies, after US President Donald Trump was treated last week with an experimental treatment from Regeneron, and he promised to make it free for Americans while promoting it, And that, according to Reuters network.
Medical experts said more data is needed to evaluate the treatment’s effectiveness before it can be used more widely.
Trump was discharged from hospital just four days after his diagnosis Coronavirus COVID-19 that causes pneumonia is enough to lower oxygen levels in the blood.
According to his doctor, blood tests on Monday revealed the infection-fighting antibodies, which a Regeneron spokesperson said may be from the treatment.
The company said it has filed an application with the US Food and Drug Administration for an Emergency Use Permit (EUA) for its antibody formulation.
The company has so far released some early data indicating its promise to treat the COVID-19 virus, and doctors were concerned that Trump’s treatment and subsequent promotion could put pressure on regulators.
Dr. Gary Kleiner, a pediatric immunologist at the University of Miami School of Medicine, and the researcher in a trial designed to see if the antibodies in Regeneron can prevent coronavirus infection, said he had been contacted by patients searching for the drug since last week.
Dr Dirk Sostman, head of the Research Network at Houston Methodist Hospital, a pilot site for antibody programs Regeneron and the Eli Lilly Company, added that more patients are requesting to participate in the antibody trial.
Dr. Anthony Fauci, the chief infectious disease expert in the United States, added, in his speech on Monday on CNN, that he “strongly doubts” that Regeneron has contributed to Trump’s progress, adding, “You cannot prove this until you do a number of studies to prove that it is.” Already working. “
Doctors confirmed that the timeline for Trump’s disease was not entirely clear.
“If he responds at a much better rate, it is because of the antibodies,” said Dr. Edward Jones Lopez, an infectious disease specialist at the University of Southern California Medical School in Los Angeles.
“Patients who could benefit from this treatment have similar traits to President Trump, as they have essentially undetectable antibodies and are in an early stage of the disease,” said Regeneron spokeswoman Alexandra Bowie.
Regeneron has received $ 450 million from the US government for up to 300,000 doses of the dual antibody cocktail, and the company said these supplies will be distributed free of charge.
On the other hand, a statement by “Eli Lilly” stated: “The mid-stage trial of testing antibody therapy showed that it helped reduce hospital admission and emergency room visits for patients with Coronavirus COVID-19 and that it is also planning to obtain approval for emergency use EUA.”